Zealand's ZUPREME-2 petrelintide trial is marked completed

The registry entry for ZUPREME-2, a Phase 2 study of Zealand Pharma's petrelintide, moved from "active, not recruiting" to "completed" on September 9, 2026 ^[1]. The trial is listed as NCT06926842 and enrolled people with overweight or obesity and type 2 diabetes ^[1]. A completed status means the study has finished running. It does not release results.

What the record shows

The change was logged by a service that snapshots ClinicalTrials.gov several times a day and compares each version with the previous one, because the registry overwrites a record rather than keeping a public history of what it used to say ^[1]. The entry lists ZUPREME-2 as a Phase 2 trial. No results have been posted ^[1].

Petrelintide is an amylin analog, a different mechanism from the GLP-1 drugs most patients know by name ^[2]. ObesityIntel, which tracks the obesity pipeline, lists petrelintide in its Phase 2 group at up to 10.7% weight loss over 42 weeks, with tolerability described as "placebo-like" and no vomiting reported in the group that received the maximum effective dose ^[2]. Those figures are attributed to petrelintide's Phase 2 program generally ^[2]; the ZUPREME-2 results themselves have not been reported.

The Roche partnership behind the drug

In 2025 Zealand and Roche signed a global partnership for petrelintide worth $1.65 billion upfront and up to about $5.3 billion including development and sales milestones ^[2]. Zealand has reported about $2.1 billion, or DKK 14.5 billion, in cash ^[2]. ObesityIntel notes that Roche now holds two separate non-incretin programs aimed at preserving lean body mass, one of them petrelintide, which it co-develops with Zealand ^[2].

The same tracker lists a Phase 2 start for a petrelintide-plus-enicepatide combination in the second half of 2026 ^[2].

Why it matters for patients

Amylin-based drugs draw interest for two reasons: how much weight they take off, and how well people tolerate them. ObesityIntel describes petrelintide's tolerability as placebo-like, with no vomiting in the maximum effective dose group, and says a successful combination could offer a real alternative for patients sensitive to GLP-1 side effects ^[2]. That is a statement about the potential of the class, not a finding from ZUPREME-2.

Type 2 diabetes is common among people seeking weight-loss treatment, and ZUPREME-2 tests petrelintide specifically in that group. Whether the drug lowers blood sugar, how much weight it takes off in this population, and how it compares with approved GLP-1 and GIP/GLP-1 drugs such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) has not been reported. The closest available comparator figure is petrelintide's 10.7% weight loss at 42 weeks against roughly 21% at 72 weeks for tirzepatide in ObesityIntel's pipeline table, but those come from different trials ^[2], so they cannot be read as a head-to-head result.

A completed status is also easy to misread. The registry change records that the trial stopped running; it says nothing about whether the drug worked or whether side effects appeared ^[1]. For anyone weighing petrelintide as a future option, that information only becomes available when the company releases the data. Until then, the trial's outcome is unknown.

What happens next

The next dated item is the petrelintide and enicepatide combination Phase 2 start, listed for the second half of 2026 under the Zealand and Roche partnership ^[2]. A date for ZUPREME-2 topline results has not been reported ^[1].